Research shows that ivonescimab improves progression-free survival in EGFR+ lung cancer

3 Min Read

In patients with non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant, ivonescimab plus chemotherapy improves progression-free survival, a study shows published online May 31 in the Journal of the American Medical Association (JAMA) to coincide with the annual meeting of the American Society of Clinical Oncologyheld from May 31 to June 4 in Chicago.

Wenfeng Fang, M.D., Ph.D., of Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues compared the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed, advanced, or metastatic non-small cell lung cancer with the EGFR variant in a double-blind, randomized phase 3 trial. A total of 322 eligible participants were enrolled across 55 sites in China. Participants received ivonescimab or placebo plus pemetrexed and carboplatin once every three weeks for four cycles, followed by maintenance therapy (161 in each group).

The researchers found that the median progression-free survival was 7.1 versus 4.8 months in the ivonescimab versus placebo group (hazard ratio, 0.46). The progression-free survival benefit in favor of patients receiving ivonescimab versus placebo was seen in almost all subgroups, including those whose disease worsened while receiving third-generation EGFR tyrosine kinase inhibitors (TKI) and those with brain metastases (hazard ratios, 0.48 and 0 ,40). respectively).

The objective response rates were 50.6 and 35.4 percent for ivonescimab and placebo, respectively. Median overall survival data were not yet mature.

“Ivonescimab plus chemotherapy significantly improved progression-free survival in patients with non-small cell lung cancer whose disease progressed while receiving EGFR-TKI treatment,” the authors write. “The safety profile was acceptable and manageable.”

See also  Research shows that experts consider influenza the top pathogen of concern with pandemic potential

One author revealed ties to the biopharmaceutical industry; the study was funded by Akeso Biopharma, which developed ivonescimab.

More information:
HARMONi-A Study Investigators et al., Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant, JAMA (2024). DOI: 10.1001/jama.2024.10613

Copyright © 2024 Health Day. All rights reserved.

Quote: Study shows ivonescimab improves progression-free survival in EGFR+ lung cancer (2024, June 6), retrieved June 6, 2024 from html

This document is copyrighted. Except for fair dealing purposes for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *